NEO 2734
Alternative Names: EP-31670; NEO-2734Latest Information Update: 07 Mar 2024
At a glance
- Originator EPIGeNE Therapeutics; Epigenetix
- Developer Epigenetix
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors; P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer; Solid tumours
Most Recent Events
- 18 Jan 2024 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 21 Dec 2022 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater, Hormone refractory) in USA (PO) (NCT05488548)
- 21 Dec 2022 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (PO) (NCT05488548)